Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
ipo
8
×
life sciences
national blog main
national top stories
new york blog main
8
×
san diego blog main
san diego top stories
san francisco blog main
startups
8
×
cancer
new york top stories
san francisco top stories
boston top stories
boulder/denver blog main
boulder/denver top stories
deals
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
eli lilly
fda
novartis
takeda pharmaceutical
allergan
alzheimer's disease
biogen
cancer immunotherapy
clinical trials
What
bio
roundup
drugs
ipo
medicines
new
pharmaceutical
black
companies
covid
deal
diamond’s
life
plans
raise
science
typically
acquisitions
activity
advance
aiming
alzheimer’s
ambys
announced
appetite
approvals
bails
big
biogen
biology
biotech
brand
bread
bridgebio
butter
buyout
cancer
capital
car
cash
Language
unset
Current search:
ipo
×
startups
×
" new york blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Synthorx Files for IPO to Advance Enhanced Cytokine Drugs
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?